How long should I continue apixaban (Eliquis) 2.5 mg twice daily for secondary prophylaxis after six months of therapy in a patient with a prior pulmonary embolism?

Duration of Apixaban 2.5 mg Twice Daily for Secondary VTE Prophylaxis

For patients with unprovoked pulmonary embolism who have completed 6 months of therapeutic anticoagulation, apixaban 2.5 mg twice daily should be continued indefinitely without a predetermined stop date, with annual reassessment of the risk-benefit balance. 1, 2

Key Decision Framework

After completing the initial 6-month treatment phase with full-dose anticoagulation, your decision depends on whether the PE was provoked or unprovoked:

If PE Was Unprovoked (No Identifiable Trigger)

• Continue apixaban 2.5 mg twice daily indefinitely 1
• Extended-phase anticoagulation has no predefined stop date 1
• Reassess the decision at least annually and whenever significant health changes occur 1
• Studies monitored patients for 2-4 years, though most continued beyond that timeframe 1

If PE Was Provoked

• Major transient risk factor (surgery >30 min with general anesthesia, hospitalization ≥3 days with acute illness, major trauma, cesarean section within 3 months): Stop anticoagulation - do not offer extended therapy 1
• Minor transient risk factor (surgery <30 min, hospitalization <3 days, estrogen therapy, pregnancy within 2 months): Generally stop anticoagulation 1

Evidence Supporting Reduced-Dose Apixaban

The FDA label specifically indicates apixaban 2.5 mg twice daily for reduction in risk of recurrent DVT/PE after at least 6 months of treatment 2. The AMPLIFY-EXT trial demonstrated that this reduced dose:

• Reduced recurrent VTE from 8.8% (placebo) to 1.7% (absolute risk reduction of 7.2%) 3
• Major bleeding rate was only 0.2% (compared to 0.5% with placebo) 3
• Mortality was lower (0.8% vs 1.7% with placebo) 3

The 2021 CHEST guidelines suggest reduced-dose apixaban (2.5 mg twice daily) over full-dose apixaban for extended-phase therapy, though this is a weak recommendation based on very low-certainty evidence 1. The rationale is to minimize bleeding risk while maintaining VTE prevention.

Critical Reassessment Points

You must reassess continuation annually, evaluating:

• Bleeding risk: New bleeding events, falls, declining renal function, new medications increasing bleeding risk
• Recurrence risk: Development of new VTE risk factors, patient preference changes
• Patient preference: Burden of daily medication, quality of life considerations

The guidelines explicitly state that offering extended therapy does not automatically mean all patients receive it - patient preference and predicted bleeding risk must influence the decision 1.

Common Pitfalls to Avoid

1. Don't assume "indefinite" means "forever without reassessment" - annual evaluation is mandatory 1
2. Don't use aspirin as a substitute - if the patient qualifies for extended anticoagulation, reduced-dose DOACs are strongly preferred over aspirin 1
3. Don't continue full-dose (5 mg twice daily) when reduced-dose is appropriate - the 2.5 mg dose provides adequate protection with lower bleeding risk for secondary prevention 1, 3
4. Don't stop at arbitrary timepoints (1 year, 2 years) without reassessing the clinical scenario - the decision should be based on ongoing risk-benefit analysis, not calendar dates 1

Real-World Application

In clinical practice with a median follow-up exceeding 2 years, low-dose apixaban showed VTE recurrence rates of only 3.7% with major bleeding of 0.3% 4. However, patients with multiple prior VTE episodes had higher recurrence risk even on reduced-dose therapy, suggesting these patients may benefit from full-dose continuation 4.